Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,136.74
(
0.51%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.65
(
2.39%
)
Bitcoin
74,444.80
(
-0.53%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: drbio45 post# 75096

Friday, 03/27/2009 9:20:08 AM

Friday, March 27, 2009 9:20:08 AM

Post# of 257253
MNTA – Thanks, drbio, for the Leerink Swann report.

Joseph Schwartz (analyst): Teva likely submitted the CP seeking to stall M-356 [generic Copaxone] in its regulatory pathway…

“Likely” strikes me as unduly timid on the analyst’s part; is there another reason why Teva would have submitted the Copaxone CP? (Rhetorical question—no need to reply.)


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today